FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085486530> ?p ?o ?g. }

• W2085486530 endingPage "310" @default.
• W2085486530 startingPage "300" @default.
• W2085486530 abstract "To date, the best results in life-supporting pig-to-primate renal xenotransplantation have been obtained in recipients exposed to long-term immunosuppression with cyclophosphamide. As this agent is frequently associated with side-effects, we have explored the potential of a mycophenolate sodium-based maintenance immunosuppression in this model. Human decay-accelerating factor (hDAF) transgenic kidneys were transplanted into splenectomized and bilaterally nephrectomized cynomolgus monkeys immunosuppressed with mycophenolate sodium, cyclosporin A and steroids, and exposed to a brief induction course with cyclophosphamide (up to four doses). After transplantation, the primates were monitored daily for biochemical and haematological evaluations and for the measurements of haemolytic anti-pig antibodies (APA). A detailed histological analysis of each explanted graft was also performed. All the animals showed very poor initial graft function but survived for up to 51 days. In contrast to our previous studies in xenograft recipients on long-term immunosuppression with cyclophosphamide, minimal or no circulating xeno-directed antibodies, as measured by the evaluation of APA titres, were detected in this series although some degree of acute humoral rejection was observed in all the explanted grafts and was the primary cause of graft failure. Furthermore, in addition to areas of humorally mediated graft damage, we have observed for the first time areas with exclusive and prominent infiltration by CD2+ and CD8+ mononuclear cells presenting patterns compatible with tubulitis, glomerulitis and arteritis, which we have called acute cellular xenograft rejection (ACXR). In addition, CD68+ infiltrating macrophages and CD20+ B-cells were also present. This study demonstrates that a triple maintenance immunosuppression with mycophenolate sodium, cyclosporin A and steroids is a viable alternative to a cyclophosphamide-based immunosuppression to obtain prolonged survival of porcine organs transplanted into primates. However, a more stringent control of antibody forming cells remains essential to further extend the survival of xenografts in this model. In addition, the use of the immunosuppressive regimen reported here in the primate is associated with the occurrence of a new category of cell-mediated xenograft injury (ACXR) whose significance has yet to be clarified." @default.
• W2085486530 created "2016-06-24" @default.
• W2085486530 creator A5001067070 @default.
• W2085486530 creator A5008794179 @default.
• W2085486530 creator A5013194878 @default.
• W2085486530 creator A5016220418 @default.
• W2085486530 creator A5017534176 @default.
• W2085486530 creator A5026997298 @default.
• W2085486530 creator A5038738846 @default.
• W2085486530 creator A5038949604 @default.
• W2085486530 creator A5053854904 @default.
• W2085486530 creator A5055986570 @default.
• W2085486530 creator A5064491710 @default.
• W2085486530 creator A5072711256 @default.
• W2085486530 creator A5082599174 @default.
• W2085486530 date "2003-06-10" @default.
• W2085486530 modified "2023-10-05" @default.
• W2085486530 title "Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts" @default.
• W2085486530 cites W1975100940 @default.
• W2085486530 cites W1978541267 @default.
• W2085486530 cites W1979950065 @default.
• W2085486530 cites W1982655337 @default.
• W2085486530 cites W1995139644 @default.
• W2085486530 cites W2006870443 @default.
• W2085486530 cites W2007516625 @default.
• W2085486530 cites W2021295767 @default.
• W2085486530 cites W2031618803 @default.
• W2085486530 cites W2032121728 @default.
• W2085486530 cites W2038502021 @default.
• W2085486530 cites W2042303293 @default.
• W2085486530 cites W2052847242 @default.
• W2085486530 cites W2054810259 @default.
• W2085486530 cites W2057632294 @default.
• W2085486530 cites W2059171126 @default.
• W2085486530 cites W2061904336 @default.
• W2085486530 cites W2062210226 @default.
• W2085486530 cites W2065021662 @default.
• W2085486530 cites W2066023848 @default.
• W2085486530 cites W2082359168 @default.
• W2085486530 cites W2087544700 @default.
• W2085486530 cites W2088143812 @default.
• W2085486530 cites W2088964434 @default.
• W2085486530 cites W2114750687 @default.
• W2085486530 cites W2121454052 @default.
• W2085486530 cites W2130983140 @default.
• W2085486530 cites W2140699817 @default.
• W2085486530 cites W2142337841 @default.
• W2085486530 cites W4248586772 @default.
• W2085486530 doi "https://doi.org/10.1034/j.1399-3089.2003.02014.x" @default.
• W2085486530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12795679" @default.
• W2085486530 hasPublicationYear "2003" @default.
• W2085486530 type Work @default.
• W2085486530 sameAs 2085486530 @default.
• W2085486530 citedByCount "78" @default.
• W2085486530 countsByYear W20854865302012 @default.
• W2085486530 countsByYear W20854865302013 @default.
• W2085486530 countsByYear W20854865302014 @default.
• W2085486530 countsByYear W20854865302015 @default.
• W2085486530 countsByYear W20854865302016 @default.
• W2085486530 countsByYear W20854865302017 @default.
• W2085486530 countsByYear W20854865302018 @default.
• W2085486530 countsByYear W20854865302019 @default.
• W2085486530 countsByYear W20854865302020 @default.
• W2085486530 countsByYear W20854865302021 @default.
• W2085486530 countsByYear W20854865302022 @default.
• W2085486530 countsByYear W20854865302023 @default.
• W2085486530 crossrefType "journal-article" @default.
• W2085486530 hasAuthorship W2085486530A5001067070 @default.
• W2085486530 hasAuthorship W2085486530A5008794179 @default.
• W2085486530 hasAuthorship W2085486530A5013194878 @default.
• W2085486530 hasAuthorship W2085486530A5016220418 @default.
• W2085486530 hasAuthorship W2085486530A5017534176 @default.
• W2085486530 hasAuthorship W2085486530A5026997298 @default.
• W2085486530 hasAuthorship W2085486530A5038738846 @default.
• W2085486530 hasAuthorship W2085486530A5038949604 @default.
• W2085486530 hasAuthorship W2085486530A5053854904 @default.
• W2085486530 hasAuthorship W2085486530A5055986570 @default.
• W2085486530 hasAuthorship W2085486530A5064491710 @default.
• W2085486530 hasAuthorship W2085486530A5072711256 @default.
• W2085486530 hasAuthorship W2085486530A5082599174 @default.
• W2085486530 hasConcept C126322002 @default.
• W2085486530 hasConcept C142724271 @default.
• W2085486530 hasConcept C203014093 @default.
• W2085486530 hasConcept C2776694085 @default.
• W2085486530 hasConcept C2776755627 @default.
• W2085486530 hasConcept C2778033501 @default.
• W2085486530 hasConcept C2778442404 @default.
• W2085486530 hasConcept C2780252810 @default.
• W2085486530 hasConcept C2911091166 @default.
• W2085486530 hasConcept C71924100 @default.
• W2085486530 hasConceptScore W2085486530C126322002 @default.
• W2085486530 hasConceptScore W2085486530C142724271 @default.
• W2085486530 hasConceptScore W2085486530C203014093 @default.
• W2085486530 hasConceptScore W2085486530C2776694085 @default.
• W2085486530 hasConceptScore W2085486530C2776755627 @default.
• W2085486530 hasConceptScore W2085486530C2778033501 @default.
• W2085486530 hasConceptScore W2085486530C2778442404 @default.
• W2085486530 hasConceptScore W2085486530C2780252810 @default.

• next